Oppenheimer Holdings, Inc. reissued their buy rating on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a research report sent to investors on Thursday morning. They currently have a $21.00 target price on the biopharmaceutical company’s stock.

VNDA has been the subject of several other reports. Zacks Investment Research raised Vanda Pharmaceuticals from a sell rating to a strong-buy rating and set a $18.00 price objective for the company in a research report on Tuesday, August 8th. Jefferies Group LLC reissued a buy rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, May 25th. BidaskClub lowered Vanda Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, August 11th. Piper Jaffray Companies set a $23.00 price objective on Vanda Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 3rd. Finally, HC Wainwright set a $18.00 price objective on Vanda Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 3rd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $21.63.

Vanda Pharmaceuticals (VNDA) opened at 18.40 on Thursday. Vanda Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $18.40. The firm’s market capitalization is $825.39 million. The firm has a 50-day moving average price of $16.42 and a 200-day moving average price of $15.18.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The business had revenue of $42.06 million during the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. Vanda Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $0.01 EPS. Equities analysts expect that Vanda Pharmaceuticals will post ($0.44) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Oppenheimer Holdings, Inc. Reaffirms “Buy” Rating for Vanda Pharmaceuticals Inc. (VNDA)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/17/oppenheimer-holdings-inc-reaffirms-buy-rating-for-vanda-pharmaceuticals-inc-vnda.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Rice Hall James & Associates LLC grew its stake in shares of Vanda Pharmaceuticals by 1.0% in the 2nd quarter. Rice Hall James & Associates LLC now owns 27,903 shares of the biopharmaceutical company’s stock valued at $455,000 after buying an additional 279 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Vanda Pharmaceuticals by 1.2% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 45,562 shares of the biopharmaceutical company’s stock valued at $638,000 after buying an additional 541 shares during the period. American International Group Inc. grew its stake in shares of Vanda Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 1,491 shares during the period. Strs Ohio grew its stake in shares of Vanda Pharmaceuticals by 4.6% in the 1st quarter. Strs Ohio now owns 49,600 shares of the biopharmaceutical company’s stock valued at $694,000 after buying an additional 2,200 shares during the period. Finally, California Public Employees Retirement System grew its stake in shares of Vanda Pharmaceuticals by 3.8% in the 2nd quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock valued at $971,000 after buying an additional 2,200 shares during the period. Institutional investors own 86.49% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.